|
|
Article: FDA Approves Labeling for Use of Xenical(R) (orlistat) in Management of Obesity in Adolescent Patients Aged 12 to 16 years; Only Prescription Weight-Loss Treatment Approved with Labeling for Use in Management of Obesity in Adolescents.
- Article from:
- PR Newswire
- Article date:
- December 15, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NUTLEY, N.J., Dec. 15 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration has approved labeling for use of the prescription weight-loss medication Xenical(R) (orlistat) in the management of obese adolescents ages 12 to 16 years. This is the first approval of its kind for a prescription weight-loss treatment.
"This is very good news for adolescents struggling with overweight and obesity," said Marc S. Jacobson, M.D., attending physician and director of the Center for Atherosclerosis Prevention in the Division of Adolescent Medicine at Schneider Children's Hospital of North Shore-Long Island Jewish Health System. "Obesity is an ...